Delving into the Latest Updates on Aclarubicin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aclacinomycin A, Aclarubicin, Aclarubicin Hydrochlorid

+ [9]

Target

DNA x Top II

Mechanism

DNA inhibitors(DNA inhibitors), Top II inhibitors(Topoisomerase II inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [5]

Active Indication

Breast CancerLeukemiaLung Cancer+ [3]

Inactive Indication-

Originator Organization

MicroBiopharm Japan Co., Ltd.

Active Organization

Astellas Pharma, Inc.

MicroBiopharm Japan Co., Ltd.Sichuan Haikang Pharmaceutical Co Ltd

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (04 Jun 1981),

LeukemiaLung CancerLymphoma+ [2]

Regulation-

Login to view timeline

Structure

Molecular FormulaC42H53NO15

InChIKeyUSZYSDMBJDPRIF-SVEJIMAYSA-N

CAS Registry57576-44-0

View All Structures (2)

BACKGROUNDAcute febrile neutrophilic dermatosis, also commonly referred to as Sweet syndrome, is often associated with tumors, infections, immune disorders and medications. FLT3 inhibitor-induced Sweet syndrome is a rare complication.METHODS AND RESULTSWe report a patient with relapsed and refractory acute monocytic leukemia harboring high-frequency FLT3-ITD and DNMT3a mutations. The FLT3 inhibitor gilteritinib was administered for reinduction therapy after failure of chemotherapy with a combination of venetoclax, decitabine, aclarubicin, cytarabine and granulocyte colony-stimulating factor. The leukemia patient achieved remission after 1 month of treatment. However, Sweet syndrome induced by gilteritinib, which was confirmed by skin biopsy, developed during induction therapy. Similar cases of Sweet syndrome following FLT3 inhibitor therapy for acute myeloid leukemia were reviewed.CONCLUSIONAttention should be given to this rare complication when FLT3 inhibitors are used for acute myeloid leukemia therapy, and appropriate treatments need to be administered in a timely manner.

01 Oct 2024·Annals of Hematology

Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review

Review

Author: Tu, Song-Tao ; Wang, Fang ; Wang, Jie-Yu ; Wang, Shi-Xuan ; Zhou, Yu-Lan ; Lv, Ke-Bing ; Li, Fei ; Tu, Ye-Chao

AbstractChronic neutrophil leukemia (CNL) is a rare and life-threatening disease. Cases of CNL combined with lymphoma are rare. Here, we report a case of CNL with T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) in a 28-year-old male. After a regimen of ruxolitinib, VICLP (Vincristine, Idarubicin, Cyclophosphamide, Prednisone, Peg-asparaginase) regimen, high-dose cytarabine, and methotrexate regimens, the patient’s bone marrow condition partially resolved. However, when the disease relapsed four months later, despite attempts with selinexor, venetoclax, and CAG(aclarubicin hydrochloride, Algocytidine, Granulocyte Stimulating Factor) chemotherapy, the leukocytes and peripheral blood primitive cells reduced, but the bone marrow did not achieve remission. This pathogenesis may be related to microenvironmental immune escape under prolonged inflammatory stimulation and gene disruption affecting protein function due to colony-stimulating factor 3 receptor gene (CSF3R) mutations. For this type of disease, early intervention may delay disease progression.

01 Oct 2024·Science of The Total Environment

The underlying mechanisms of oxytetracycline degradation mediated by gut microbial proteins and metabolites in Hermetia illucens

Article

Author: Qin, Yuanhang ; Wang, Cunwen ; Li, Yun ; Wang, Tielin ; Cao, Qingcheng ; Liu, Cuncheng

Hermetia illucens larvae can enhance the degradation of oxytetracycline (OTC) through its biotransformation. However, the underlying mechanisms mediated by gut metabolites and proteins are unclear. To gain further insights, the kinetics of OTC degradation, the functional structures of gut bacterial communities, proteins, and metabolites were investigated. An availability-adjusted first-order model effectively evaluated OTC degradation kinetics, with degradation half-lives of 4.18 and 21.71 days for OTC degradation with and without larval biotransformation, respectively. Dominant bacteria in the larval guts were Enterococcus, Psychrobacter, Providencia, Myroides, Enterobacteriaceae, and Lactobacillales. OTC exposure led to significant differential expression of proteins, with functional classification revealing involvement in digestion, transformation, and adaptability to environmental stress. Upregulated proteins, such as aromatic ring hydroxylase, acted as oxidoreductases modifying the chemical structure of OTC. Unique metabolites, aclarubicin and sancycline identified were possible OTC metabolic intermediates. Correlation analysis revealed significant interdependence between gut bacteria, metabolites, and proteins. These findings reveal a synergistic mechanism involving gut microbial metabolism and enzyme structure that drives the rapid degradation of OTC and facilitates the engineering applications of bioremediation.

100 Deals associated with Aclarubicin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Aclarubicin Hydrochloride	L01DB04	DB11617

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	JP	Astellas Pharma, Inc.	04 Dec 1981
Leukemia	JP	MicroBiopharm Japan Co., Ltd.	04 Jun 1981
Lung Cancer	JP	MicroBiopharm Japan Co., Ltd.	04 Jun 1981
Lymphoma	JP	MicroBiopharm Japan Co., Ltd.	04 Jun 1981
Ovarian Cancer	JP	MicroBiopharm Japan Co., Ltd.	04 Jun 1981
Stomach Cancer	JP	MicroBiopharm Japan Co., Ltd.	04 Jun 1981

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05662956 (EHA2024) Manual	Phase 2	Acute Myeloid Leukemia First line \| Induction	67	venetoclax + azacitidine + CYTARABINE + ACLARUBICIN + G-CSF	(xibcrorxib) = ctidhonsrs ahmabeubsq (tqnblxbqjv ) View more	Positive	14 May 2024
ASH2018	Not Applicable	Gastrointestinal Neoplasms	535	Apixaban	(nmwhqmbqar) = hfraygddes rvlozvutxr (aqalgllyaf ) View more	-	29 Nov 2018
ASH2018	Not Applicable	Gastrointestinal Neoplasms	535	Rivaroxaban	(nmwhqmbqar) = eavutvcblb rvlozvutxr (aqalgllyaf ) View more	-	29 Nov 2018